Clinical trials: Myasthenia Gravis Exacerbations
Myasthenia Gravis Exacerbations
A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations
This was a multicenter, prospective, open-label, non-controlled study to assess the efficacy and safety of an IV dose of 2 g/kg of IGIV-C in subjects with MG exacerbations.
- Trial name
- NCT02413580
- Testing
- IGIV-C
- Where
- 31 sites in Argentina, Belgium and 10 more
- Volunteers
- 49 people
- Sponsor
- Grifols Therapeutics LLC
Myasthaenia Gravis, Myasthenia
Myasthenia Gravis Foundation of America Global MG Patient Registry
The goal of this observational study is to learn about the experiences of people living with Myasthenia Gravis (MG) in the United States.
- Conditions
- Myasthaenia Gravis, Myasthenia, Myasthenia Gravis Associated with Thymoma, Myasthenia Gravis Crisis
- Trial name
- MGFAPR (NCT06617741)
- Where
- United States
- Volunteers
- 3,800 people
- Sponsor
- Myasthenia Gravis Foundation of America
Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations
Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
This study plans to learn more about if the drug efgartigimod can be used in the hospital to treat exacerbations in participants with myasthenia gravis (MG).
- Conditions
- Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis
- Trial name
- NCT06860633
- Testing
- Efgartigimod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Myasthenia Gravis (MG), Myasthenia Gravis, Generalized
AXIS MG Patient Registry
The goal of the AXIS Autoimmune Neurology Registry is to learn about the experiences of adults living with autoimmune neurological disorders, starting with myasthenia gravis (MG), over time.
- Conditions
- Myasthenia Gravis (MG), Myasthenia Gravis, Generalized, Myasthenia Gravis, Ocular, Myasthenia Gravis Crisis
- Trial name
- AXIS (NCT07761026)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Autoimmune Neurology Alliance
Generalized Myasthenia Gravis (gMG)
Zilucoplan for Severe gMG Exacerbations
This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks.
- Trial name
- NCT07215949
- Testing
- Zilucoplan®
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Miriam Freimer